Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.55 |
| ▸ | CA9 | Q16790 | 4/20 | 0.55 |
| ▸ | NQO2 | P16083 | 2/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19713074 | 0.88 | CA12 (0.50) | CA12CA9NQO2DAOCYP2A6 | |
| SCHEMBL1978356 | 0.80 | CA12 (0.49) | CA12CA9KDM4EPOLBMAPT | |
| SCHEMBL98175 | 0.80 | CA12 (0.49) | CA12CA9KDM4EPOLBMAPT | |
| SCHEMBL10064553 | 0.77 | MCHR1 (0.48) | CA12CA9PDE3BPDE3AGAA | |
| SCHEMBL1137647 | 0.77 | CA12 (0.43) | CA12CA9KDM4EMEN1MAPT | |
| SCHEMBL28427455 | 0.76 | CA12 (0.44) | CA12CA9NQO2MAPTMCL1 | |
| SCHEMBL19751536 | 0.76 | CA12 (0.49) | CA12CA9NQO2MAPTLMNA | |
| SCHEMBL29153231 | 0.76 | CA12 (0.49) | CA12CA9NQO2KDM4EMAPT | |
| SCHEMBL22901566 | 0.76 | ABCB1 (0.51) | MAPTHTTSMN1; SMN2 | |
| SCHEMBL9820774 | 0.76 | MCHR1 (0.49) | CA12CA9MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539244-B | Preparation method of moxifloxacin hydrochloride | 沈阳药科大学 | 2023-04-14 | — | — | CN | disclosed |
| CN-114539244-A | Preparation method of moxifloxacin hydrochloride | 沈阳药科大学 | 2022-05-27 | — | — | CN | disclosed |
| EP-2941423-B1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | UNIV SOUTHERN CALIFORNIA (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-2941423-B1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | UNIV SOUTHERN CALIFORNIA (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10889563-B2 | Deoxyuridine triphosphatase inhibitors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2021-01-12 | — | — | US | disclosed |
| US-10889563-B2 | Deoxyuridine triphosphatase inhibitors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190270719-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | PRESTWICK CHEMICAL, SAS (FR) | 2019-09-05 | — | — | US | disclosed |
| US-20190270719-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | PRESTWICK CHEMICAL, SAS (FR) | 2019-09-05 | — | — | US | disclosed |
| US-10227326-B2 | Deoxyuridine triphosphatase inhibitors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227326-B2 | Deoxyuridine triphosphatase inhibitors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2019-03-12 | — | — | US | disclosed |
| CN-1200938-C | Process for preparing 8-methoxy-quinolone | BAYER MEDICAL AND HEALTH CARE (DE) | 2005-05-11 | — | — | CN | disclosed |
| CN-1200938-C | Process for preparing 8-methoxy-quinolone | BAYER MEDICAL AND HEALTH CARE (DE) | 2005-05-11 | — | — | CN | disclosed |
| CN-1151151-C | Process for preparing 8-methoxy-quinolone carboxylic acids | — | 2004-05-26 | — | — | CN | disclosed |
| CN-1418879-A | Process for preparing 8-methoxy-quinolone | BAYER AG (DE) | 2003-05-21 | — | — | CN | disclosed |
| CN-1418879-A | Process for preparing 8-methoxy-quinolone | BAYER AG (DE) | 2003-05-21 | — | — | CN | disclosed |
| EP-1017392-B1 | MEDICAMENT FORMULATION WITH A CONTROLLED RELEASE OF AN ACTIVE AGENT | BAYER AG (DE) | 2002-07-17 | — | — | EP | disclosed |
| US-6270799-B1 | 1-CYCLOPROPYL-7-((S,S)-2,8-DIAZABICYCLO(4.3.0)NON-8-YL)-6-FLUO RO-1, 4-DIHYDRO-8-METHOXY-4-OXO-3-QUINO-LONECARBOXYLIC ACID AND/OR PHARMACEUTICALLY TOLERABLE SALTS | BAYER AKTIENGESELLSCAHFT (DE) | 2001-08-07 | — | — | US | disclosed |
| CN-1279683-A | Process for preparing 8-methoxy-quinolone carboxylic acids | BAYER AG (DE) | 2001-01-10 | — | — | CN | disclosed |
| EP-1017392-A1 | MEDICAMENT FORMULATION WITH A CONTROLLED RELEASE OF AN ACTIVE AGENT | Bayer Aktiengesellschaft (DE) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999015172-A1 | MEDICAMENT FORMULATION WITH A CONTROLLED RELEASE OF AN ACTIVE AGENT | BAYER AKTIENGESELLSCHAFT (DE) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270719-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | CA12 4496/4885CA9 3472/4885NQO2 350/4885 |
| US-10889563-B2 | Deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | CA12 4496/4885CA9 3472/4885NQO2 350/4885 |
| US-10227326-B2 | Deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | CA12 4496/4885CA9 3472/4885NQO2 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.